- Your cart is empty
- Continue Shopping
Sickle Cell Disease Statistics: How Many People Are Affected? [2025]
- Stats & Data
- Posted on
-
by enavec_pharmacy
- 0 comments
![Sickle Cell Disease Statistics: How Many People Are Affected? [2025]](https://enavecpharmacy.com/wp-content/uploads/2026/04/Designer-9.png)
📊 Statistics & Data Report
Global
Africa
Nigeria
Treatment
Updated 2025
Sickle Cell Disease Statistics: How Many People Are Affected? [2025]
From 5.46 million in 2000 to 7.74 million today — the world's most neglected genetic disease is growing. Here is every number you need, sourced and verified.
🔬 Primary Answer
7.74M
People living with sickle cell disease globally in 2021
Source: IHME / GBD 2021 Study · Lancet Haematology, June 2023
🔍 Commonly Searched Topics
- How many people have sickle cell in Nigeria?
- Sickle cell disease death rate Africa
- Is sickle cell curable in 2024/2025?
- Sickle cell prevalence by country
- Life expectancy with sickle cell disease
- How many babies born with sickle cell yearly?
🌍 Where Readers Come From
- Nigeria — largest SCD burden globally
- Ghana, Cameroon, DRC, Uganda
- United Kingdom — 15,000+ patients
- United States — 100,000+ patients
- India, Saudi Arabia, Caribbean
- Healthcare professionals worldwide
🌐
Section 1
Global Prevalence — The Big Numbers
Between 2000 and 2021, the number of people living with sickle cell disease grew by over 41%. These are the headline statistics from the most comprehensive global study ever conducted on SCD.
7.74M
People living with SCD globally
Up from 5.46 million in 2000 — a 41.4% increase driven by population growth in sub-Saharan Africa and the Caribbean.
IHME / GBD 2021 — Lancet Haematology, 2023
515,000
Babies born with SCD per year (2021)
79% of these births occur in sub-Saharan Africa. Every 60 seconds, a child is born with sickle cell disease somewhere in the world.
IHME / GBD 2021 — Lancet Haematology, 2023
376,000
Actual deaths attributed to SCD (2021)
True total mortality — nearly 11 times higher than the officially recorded 34,400 cause-specific deaths.
IHME / GBD 2021 — Lancet Haematology, 2023
5%
World population carrying SCD trait gene
Approximately 5% of the global population carries a haemoglobin disorder trait. In some regions, carrier rates reach 25%.
WHO / AFRO Regional Office
81,100
Under-5 child deaths from SCD (2021)
SCD is the 12th leading cause of death in children under 5 globally — 28 places higher than cause-specific figures alone suggest.
IHME / GBD 2021 — Lancet Haematology, 2023
300,000+
Severe haemoglobin disorder births per year
Historical WHO estimate. The majority are in low- and middle-income countries with the fewest healthcare resources.
WHO / AFRO Regional Office
🚨 The Hidden Reality
SCD deaths are 11 times higher than recorded — the world has been massively undercounting
Official cause-specific mortality recorded just 34,400 SCD deaths in 2021. But when the full epidemiological burden — secondary complications, organ failure, infections — is counted, total deaths reach 376,000. This mismatch is most extreme in South Asia (67× higher) and sub-Saharan Africa (9× higher), where data systems are weakest and underdiagnosis most severe.
Source: IHME / GBD 2021 Sickle Cell Disease Study · The Lancet Haematology · June 15, 2023 · doi: 10.1016/S2352-3026(23)00118-7
⏳
Section 2
Life Expectancy Gap — The 20-Year Penalty
Even in countries with advanced healthcare systems, people with SCD face a severe life expectancy penalty. In low-resource settings, the gap is catastrophic.
SCD Patients Life Expectancy (USA)
52.6
years — publicly insured patients living with SCD in the United States
Blood Advances / ASH · Jiao et al., March 2023
General US Population Life Expectancy
76.4
years — average US population (CDC, 2023)
CDC National Vital Statistics, 2023
⚡ Gap = ~24 years of life lost due to sickle cell disease — even in the United States
55.0 yrs
SCD female life expectancy (USA)
vs 79.3 years for the general US female population — a gap of over 24 years.
Blood Advances / ASH · 2023
49.3 yrs
SCD male life expectancy (USA)
vs 73.5 years for the general US male population — a gap of over 24 years.
Blood Advances / ASH · 2023
<5 yrs
Median survival — Africa (without care)
In most of sub-Saharan Africa, the majority of children with severe SCD die before age 5, usually from infection or severe anaemia.
WHO / AFRO Regional Office
🇳🇬
Section 3 — Nigeria Deep Dive
Nigeria: The Global Epicentre of Sickle Cell Disease
Nigeria holds the single largest burden of sickle cell disease of any country on earth. Every statistic below is sourced from peer-reviewed studies, WHO/AFRO, or FMOH data.
Nigeria SCD Statistics
World's #1 Burden Country
150,000
babies born with SCD in Nigeria per year
Frontiers / Lancet Haematology, 2025
50M+
Nigerians carry the sickle cell trait (HbAS)
~1 in 4 Nigerians — FMOH
1–3%
National SCD prevalence across states
Adigwe et al., Int J Gen Med, 2023
20–30%
Carrier prevalence in high-burden states
WHO/AFRO Regional Office
Nigeria is recognised as the country with the highest burden of sickle cell disease globally. With 100,000 to 150,000 babies born with SCD every year, Nigeria alone accounts for a significant fraction of total global SCD births (515,000 globally in 2021).
The carrier rate — estimated at approximately 50 million Nigerians (roughly 1 in 4) — is the primary engine of new SCD cases. When two carriers have children, each child has a 25% chance of being born with the full disease. Without mandatory premarital genotype screening, this cycle continues unchecked.
In Nigeria's high-burden states — particularly in the South-East (Anambra, Imo, Enugu, Abia, Ebonyi) and South-South geopolitical zones — SCD contributes up to 7–16% of under-five mortality, making it one of the leading child killers in these regions.
Historical note: Nigeria was among the first African countries to establish a national SCD control programme. The FMOH issued its National Guideline for the Control and Management of Sickle Cell Disease in 2014 — yet implementation gaps, drug shortages, and lack of universal newborn screening remain critical challenges in 2025.
🗺️
Section 4
SCD Burden by Region
Carrier prevalence and disease burden vary dramatically by geography. Sub-Saharan Africa carries the overwhelming majority of the world's SCD burden.
📋
Section 5 — Quick Reference
Key Statistics at a Glance
All headline statistics in one place. Journalists and researchers may cite these figures with attribution to the primary sources listed.
Sickle Cell Disease — Master Data Table
Cite with attribution to enavecpharmacy.com
| Statistic | Figure | Year | Source |
|---|---|---|---|
| People living with SCD globally | 7.74 million | 2021 | IHME / GBD 2021, Lancet Haematology |
| SCD global prevalence in 2000 | 5.46 million | 2000 | IHME / GBD 2021 Study |
| New SCD births worldwide per year | 515,000 | 2021 | IHME / GBD 2021, Lancet Haematology |
| % of SCD births in sub-Saharan Africa | ~79% | 2021 | IHME / GBD 2021 |
| Total SCD deaths (true burden) | 376,000 | 2021 | IHME / GBD 2021, Lancet Haematology |
| Officially recorded SCD deaths | 34,400 | 2021 | IHME / GBD 2021 (cause-specific) |
| SCD under-5 deaths globally | 81,100 | 2021 | IHME / GBD 2021 |
| SCD ranking as child death cause | 12th globally | 2021 | IHME / GBD 2021 |
| Nigerians born with SCD per year | 100,000–150,000 | 2023 | Frontiers / Lancet |
| Nigerians carrying the SCD trait | ~50 million | 2023–2024 | FMOH / Peer-reviewed studies |
| SCD carrier prevalence — Nigeria | 20–30% | Current | WHO/AFRO Regional Office |
| SCD national prevalence — Nigeria | 1–3% | 2023 | Adigwe et al., Int J Gen Med, 2023 |
| SCD contribution to under-5 mortality (Africa) | 7–16% | 2025 | Nature Comms Medicine / SickleInAfrica |
| SCD patients in the USA | ~100,000 | 2023–2024 | CDC / CMS / ASH |
| SCD life expectancy (USA, publicly insured) | 52.6 years | 2023 | Blood Advances / ASH — Jiao et al. |
| Life expectancy gap vs general population | >20 years | 2023 | CMS, ASH, Blood Advances 2023 |
| NHS hospital admissions for SCD (England) | 32,000+ | 2023–24 | NHS England, Jan 2025 |
| SCD crisis admissions (England) | ~14,000 | 2023–24 | NHS England, Jan 2025 |
| Global cell/gene therapy spending | $5.9 billion | 2023 | Congressional Budget Office, 2024 |
| Historical: SCD annual births (early 2000s) | >300,000 | Pre-2010 | WHO Global Estimate |
📅
Section 6
Historical Timeline — From Discovery to Cure
Over 115 years of discovery, data, and progress — from the first documented case to the world's first CRISPR gene therapy.
1910
First documented SCD case in medical literature
Dr. James B. Herrick, a Chicago physician, describes the case of a student from Grenada with "peculiar elongated and sickle-shaped" red blood cells. This marks the first clinical description of sickle cell disease in Western medical literature.
Source: NEJM / Herrick, 1910
1949
Linus Pauling identifies SCD as a "molecular disease"
Nobel laureate Linus Pauling demonstrates that haemoglobin from SCD patients is chemically distinct from normal haemoglobin — the first time a disease was traced to an abnormal protein. A landmark in molecular medicine.
Source: Science Journal, 1949 — Pauling et al.
1972
USA launches first national SCD screening programme
The US Sickle Cell Anemia Control Act of 1972 authorises the first national programme for SCD — a major public health milestone that would set the template for other countries.
Source: US National Archives — Public Law 92-294
1995
Hydroxyurea approved as first SCD-specific drug (USA)
The FDA approves hydroxyurea — the first and for decades the only drug specifically for SCD. Clinical trials show it reduces painful crises by approximately 50% in adults, prolonging life significantly.
Source: FDA approval records, 1995
2014
Nigeria publishes National SCD Guideline
The Federal Ministry of Health (FMOH) releases the National Guideline for the Control and Management of Sickle Cell Disease — a significant policy step for a country bearing the world's highest SCD burden.
Source: FMOH Nigeria, 2014
2021
GBD Study reveals 7.74 million people living with SCD
The Global Burden of Disease 2021 study — the most comprehensive analysis ever — reveals that 7.74 million people live with SCD globally, up 41.4% since 2000, and that actual mortality is 11× higher than official records suggest.
Source: IHME / GBD 2021 — Lancet Haematology, June 2023
Dec 2023
🧬 World's first CRISPR gene therapy approved for SCD
The FDA approves Casgevy (exagamglogene autotemcel / exa-cel) — the world's first CRISPR-based gene therapy for SCD. Clinical trials showed a functional cure in 96.6% of participants. Price: approx. $2.2 million per treatment in the USA.
Source: FDA press release, Dec 8, 2023 · Front Line Genomics, 2026
Jan 2025
NHS England approves CRISPR therapy for SCD patients
NHS England announces that Casgevy (exa-cel) will be offered to eligible patients — the first time this therapy is available on a national health service outside the USA. NHS struck a deal at a reduced price from the £1.65 million list price.
Source: NHS England press release, January 31, 2025
💊
Section 7
Treatment Landscape — 2025 Status
Treatment options for SCD range from simple affordable medicines to $2 million gene therapies — but access is profoundly unequal across the world.
Hydroxyurea
First SCD-specific drug (FDA 1995). Reduces pain crises by ~50%, increases foetal haemoglobin. Affordable — yet inaccessible to most SCD patients in Africa due to supply chain and cost barriers.
Standard of Care
Blood Transfusions
Regular transfusions reduce sickling and prevent stroke in high-risk children. Used widely in Nigeria and Africa — but chronic transfusion leads to iron overload requiring additional treatment.
Standard of Care
Stem Cell Transplant
Can be curative — but requires a genetically matched donor (limited for African-heritage patients), carries significant side effects, and is not accessible in most African healthcare systems.
Limited Access
Casgevy (CRISPR)
World's first CRISPR gene therapy — approved FDA (Dec 2023) and NHS (Jan 2025). Functional cure in 96.6% of trial participants. Cost: ~$2.2M (USA). Not yet available in Nigeria or Africa.
Approved (US/UK)
Lyfgenia (Gene Therapy)
Second gene therapy approved by FDA in December 2023. Uses a lentiviral vector to produce anti-sickling haemoglobin. Also approved for SCD in the US alongside Casgevy.
Approved (USA)
Prime Editing (Research)
Next-generation gene editing that can precisely restore the wild-type HBB gene. Demonstrated in cell models (April 2023, Liu Lab). More accurate than CRISPR. Clinical trials pending.
Emerging
📌
Section 8 — Key Takeaways
What the Data Tells Us
-
1SCD is far deadlier than records show. Official figures record 34,400 deaths in 2021 — but the true total mortality burden is 376,000, making SCD one of the most undercounted diseases in global health data. (IHME / GBD 2021)
-
2Nigeria bears a disproportionate burden. With 100,000–150,000 SCD births per year and ~50 million carriers, Nigeria is the undisputed global epicentre — yet newborn screening remains absent at scale and treatment access is severely limited outside tertiary hospitals.
-
3Even in advanced healthcare systems, SCD shortens life by 20+ years. US patients live to an average of 52.6 years versus 76.4 for the general population. In sub-Saharan Africa without care, most children don't survive past age 5. (ASH / Blood Advances, 2023)
-
4A cure now exists — but only for the wealthy. Casgevy achieved a functional cure in 96.6% of clinical trial participants. However, at $2.2 million per treatment, it is inaccessible to the 79% of SCD patients who live in sub-Saharan Africa.
-
5Prevention via genotype testing remains the most cost-effective solution for Nigeria. Universal premarital and prenatal genotype screening — a simple, inexpensive blood test — could dramatically reduce new SCD births. Carrier rate awareness is still critically low in rural areas.
❓
Section 9 — FAQ
Frequently Asked Questions
Nigeria has the highest sickle cell disease burden in the world. An estimated 100,000 to 150,000 babies are born with SCD in Nigeria every year. The national SCD prevalence is between 1% and 3%, and approximately 50 million Nigerians carry the sickle cell trait (HbAS genotype) — roughly 1 in every 4 Nigerians. In high-burden states (South-East, South-South), carrier rates reach 20–30% of the population (WHO/AFRO; Adigwe et al., Int J Gen Med, 2023).
Official cause-specific statistics recorded 34,400 SCD deaths globally in 2021. However, the IHME / GBD 2021 study revealed the true total mortality burden is 376,000 deaths per year — nearly 11 times higher. This gap reflects deaths from SCD-related complications not attributed to SCD in death certificates. Sub-Saharan Africa and South Asia account for the largest share of these hidden deaths.
In the USA, the average life expectancy for publicly insured SCD patients is approximately 52.6 years — over 24 years less than the general US population (76.4 years). In sub-Saharan Africa without adequate care, the majority of children with severe SCD die before age 5, usually from infections or severe anaemia (WHO/AFRO). With the new CRISPR gene therapy (Casgevy), early trial participants appear to have been functionally cured — but only for those who can access it.
A functional cure now exists. In December 2023, the FDA approved Casgevy — the world's first CRISPR-based gene therapy for SCD. Clinical trials showed a functional cure in 96.6% of participants. In January 2025, NHS England also approved the therapy. However, at approximately $2.2 million per treatment, it is unavailable to the vast majority of SCD patients in Africa and developing countries.
Nigeria has the world's highest sickle cell disease burden of any single country, with 100,000–150,000 new SCD births per year and ~50 million carriers. Other high-burden countries include the DRC, Ghana, Cameroon, Uganda, Tanzania, and India. Globally, 79% of all SCD births occur in sub-Saharan Africa (IHME / GBD 2021).
The national carrier rate (sickle cell trait — HbAS genotype) is approximately 20–30% in high-burden states, with a national average of roughly 1 in 4 Nigerians (~50 million people) being carriers (FMOH / WHO/AFRO). When two carriers have children, each pregnancy has a 25% chance of producing a child with full SCD (HbSS) and a 50% chance of producing another carrier.
🔍 Related Searches
📎
📎 How to Cite This Page
APA Format
Enavec Pharmacy. (2025, April). Sickle cell disease statistics [2025]: Global, Africa & Nigeria data. Enavec Pharmacy. https://enavecpharmacy.com/sickle-cell-disease-statistics
MLA Format
Enavec Pharmacy. "Sickle Cell Disease Statistics [2025]: Global, Africa & Nigeria Data." Enavec Pharmacy, April 2025, enavecpharmacy.com/sickle-cell-disease-statistics.
Plain Text
Source: Enavec Pharmacy (April 2025). Sickle Cell Disease Statistics [2025]. Retrieved from enavecpharmacy.com/sickle-cell-disease-statistics
📚 Primary Sources & Methodology
Every statistic on this page is sourced from peer-reviewed journals, WHO/AFRO official data, or national health authority records. All sources are named, dated, and verifiable.
1
IHME / GBD 2021 Sickle Cell Disease Study. Thomson et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021. The Lancet Haematology. June 15, 2023. doi: 10.1016/S2352-3026(23)00118-7
2
WHO / AFRO Regional Office. Sickle-cell disease fact sheet. World Health Organization, African Region. who.int/news-room/fact-sheets/detail/sickle-cell-disease. Updated August 2025.
3
ASH / Blood Advances. Jiao B, Johnson KM, Ramsey SD et al. Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries. Blood Advances. March 16, 2023. doi: 10.1182/bloodadvances.2022009202
4
Adigwe OP, Onavbavba G, Onoja SO. Impact of sickle cell disease on affected individuals in Nigeria: a critical review. International Journal of General Medicine. 2023;16:3503-3515. doi: 10.2147/IJGM.S410015
5
NHS England. Revolutionary gene-editing therapy for sickle cell 'offers hope of a cure' for NHS patients. Press Release, January 31, 2025. england.nhs.uk
6
FDA. FDA Approves First Gene Therapies to Treat Patients With Sickle Cell Disease. Press Release, December 8, 2023. fda.gov
7
Nature Communications Medicine. Amuzu et al. Clinical manifestations of sickle cell disease in Africa. June 18, 2025. doi: 10.1038/s43856-025-00954-z
8
FMOH Nigeria. National Guideline for the Control and Management of Sickle Cell Disease. Federal Ministry of Health, Abuja. 2014.
9
CMS / Biden-Harris Administration. Announces Action to Increase Access to Sickle Cell Disease Treatments. Centers for Medicare & Medicaid Services, 2023. cms.gov
10
Congressional Budget Office. How Increased Use of Gene Therapy Treatment for Sickle Cell Disease Could Affect the Federal Budget. December 2024. cbo.gov
11
Frontiers in Health Services. Improving access to healthcare services for sickle cell disease patients in Nigeria. July 28, 2025. doi: 10.3389/frhs.2025.1466299
12
Front Line Genomics. Sickle Cell Disease: A 2026 Update. frontlinegenomics.com, March 2026.
Found this helpful? Share it:
⚠️
Medical & Affiliate Disclaimer This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement or medication. Some links in this post are affiliate links - if you purchase through them, Enavec Pharmacy may earn a small commission at no extra cost to you.
